Results 131 to 140 of about 10,862 (159)

Reduction of Brain β-Amyloid（Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments （APP-CTFs) and Aβ Clearance

Reduction of Brain β-Amyloid（Aβ) by Fluvastatin, a Hydroxymethylglutaryl-CoA Reductase Inhibitor, through Increase in Degradation of Amyloid Precursor Protein C-terminal Fragments （APP-CTFs) and Aβ Clearance
openaire  

Some of the next articles are maybe not open access.

Related searches:

The Natural Products as Hydroxymethylglutaryl-Coa Reductase Inhibitors

Letters in Drug Design and Discovery, 2019
High cholesterol and triglyceride levels are mainly related to further generation of life-threating metabolism disorders including cardiovascular system diseases. Therefore, hypercholesterolemia (i.e., also referred to as hyperlipoproteinemia) is a serious disease state, which must be controlled.
Hayrettin Ozan Gülcan, Serkan Yigitkan, İlkay Erdogan Orhan   +2 more
exaly   +4 more sources

The effect of substrates and competitive inhibitors on the phosphatase-dependent activation of hepatic hydroxymethylglutaryl CoA reductase

Archives of Biochemistry and Biophysics, 1986
Previous studies have demonstrated that the in vitro activation of microsomal hepatic hydroxymethylglutaryl (HMG) CoA reductase by dephosphorylation is inhibited by HMG CoA or NADPH, the substrates of HMG CoA reductase (13). In the present study the effect of three competitive inhibitors of HMG CoA reductase on the activation of HMG CoA reductase was ...
K R Feingold, Arthur H Moser, K R Feingold   +2 more
exaly   +3 more sources

Effect of Hydroxymethylglutaryl-CoA Reductase Inhibitors on the Functional Properties of Erythrocyte Membranes

Experimental and Molecular Pathology, 1993
We studied 56 patients affected by primary hypercholesterolemia treated with placebo for 1 month and with simvastatin (20 mg/day) or pravastatin (20 mg/day) for 6 months during a double-blind clinical trial. At 1-month intervals we determined the following parameters in the serum: total and HDL cholesterol, triglycerides, and apolipoprotein A-1 and B ...
R A, Rabini, M, Polenta, R, Staffolani, M, Tocchini, R, Signore, I, Testa, L, Mazzanti   +6 more
openaire   +2 more sources

Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines

Journal of Cancer Research and Clinical Oncology, 1995
Competitive inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase are currently used to treat patients with hypercholesterolaemia. These inhibitors affect not only cholesterol biosynthesis, but also the production of non-steroidal mevalonate derivatives, that are involved in a number of growth-regulatory processes.
A, Gebhardt, A, Niendorf
openaire   +2 more sources

Hydroxymethylglutaryl–CoA reductase inhibitor inhibits induction of nitric oxide synthase in 3T3–L1 preadipocytes

Life Sciences, 2008
Preadipocytes are considered to play a role in adipose tissue inflammation in obesity. The purpose of this study was to determine whether hydroxymethylglutaryl-CoA reductase inhibitor (statin) modulates the nitric oxide (NO) production via inducible NO synthase (iNOS) in preadipocytes.
Kazushige, Dobashi, Shunsuke, Araki, Kazuyasu, Kubo, Rinko, Kawagoe, Yukiyo, Yamamoto, Akira, Shirahata   +5 more
openaire   +2 more sources

Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.

Pharmacological reports : PR, 2010
Healthy endothelium is essential for undisturbed functioning of the cardiovascular system, while endothelial dysfunction leads to its various pathologies. For example endothelial dysfunction precedes clinical symptoms of atherothrombosis, such as acute coronary syndrome, ischemic stroke, peripheral arterial disease or diabetic microangiopathies e.g ...
Stefan, Chłopicki, Ryszard J, Gryglewski   +1 more
openaire   +1 more source

Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.

Iranian journal of kidney diseases, 2009
High serum levels of lipoprotein(a) and homocysteine are risk factors of cardiovascular disease which are prevalent in patients on hemodialysis. Controversy exists about the effects of hydroxymethylglutaryl-CoA reductase inhibitors on serum lipoprotein(a) levels in patients on hemodialysis.
Mir Hatef, Shojaei, Mamhmoud, Djalali, Fereydoun, Siassi, Mohammad Reza, Khatami, Mohammad Ali, Boroumand, Mohammad Reza, Eshragian   +5 more
openaire   +1 more source

Effect of hydroxymethylglutaryl-CoA reductase inhibitors on low-density lipoprotein cholesterol, interleukin-6, and high-sensitivity C-reactive protein in end-stage renal disease.

Iranian journal of kidney diseases, 2011
INTRODUCTION. This study was conducted to determine the effect of statins on the serum levels of interleukin-6 (IL-6), low-density lipoprotein cholesterol (LDLC), and high-sensitivity C-reactive protein (HSCPR). MATERIALS AND METHODS. This randomized clinical trial was carried out on 95 hemodialysis patients divided into three groups of atorvastatin ...
Alireza, Soliemani, Hassan, Nikoueinejad, Mashallah, Tabatabaizade, Elaheh, Mianehsaz, Mohamadreza, Tamadon   +4 more
openaire   +1 more source